1
================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.20549
--------------
FORM 8-K
CURRENT REPORT
--------------
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
--------------------------------------
Date of Report (Date of earliest event reported): May 4, 2000
IMMUNOGEN, INC.
(Exact name of registrant as specified in its Charter)
Massachusetts 0-17999 04-2726691
------------- ------------ ----------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation File Number) Identification No.)
333 Providence Highway, Norwood, Massachusetts 02062
----------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (781) 769-4242
================================================================================
Page 1 of 6
2
ITEM 5. OTHER EVENTS
On May 4, 2000, ImmunoGen, Inc. and Genentech, Inc. announced that Genentech has
exclusively licensed ImmunoGen's maytansinoid Tumor-Activated Prodrug (TAP)
technology for use with anti-HER2 antibodies such as Herceptin. Under the terms
of the agreement, Genentech will receive exclusive worldwide rights to
commercialize anti-HER2 targeting products using ImmunoGen's maytansinoid TAP
platform. Genentech will be responsible for manufacturing, product development
and marketing of products resulting from the license; ImmunoGen will be
reimbursed for any preclinical and clinical materials that it makes under the
agreement. ImmunoGen will receive an up-front payment of $2 million. In addition
to royalties on net sales, the terms of the agreement include milestone
payments, assuming all benchmarks are met, for potentially up to $40 million.
The press release announcing the exclusive license agreement is incorporated
herein by reference and filed as exhibit 99.1 hereto.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(C) Exhibits.
99.1 The Registrant's Press Release dated May 4, 2000.
Page 2 of 6
3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereto duly authorized.
ImmunoGen, Inc.
(Registrant)
Date: May 4, 2000 /s/Kathleen A. Carroll
--------------------------------------
Kathleen A. Carroll
Vice President, Finance and
Administration, and principal
financial officer
Page 3 of 6
4
EXHIBIT INDEX
Exhibit Sequential
Number Description Page Number(s)
99.1 The Registrant's Press Release
dated May 4, 2000 5
Page 4 of 6